Key regions: Australia, Germany, United Kingdom, United States, France
The demand for immunosuppressants in Zambia has been on a steady rise in recent years.
Customer preferences: Zambian customers have shown a preference for immunosuppressants that are affordable and readily available. Due to the high cost of healthcare in the country, patients are more likely to opt for generic brands over branded drugs. Additionally, many patients prefer to purchase their medication from local pharmacies rather than hospitals, as they perceive the former to be more convenient and accessible.
Trends in the market: One of the key drivers of the immunosuppressants market in Zambia is the increasing prevalence of autoimmune diseases and organ transplants. As the country's healthcare infrastructure continues to develop, more patients are being diagnosed with these conditions and are in need of immunosuppressant therapy. Furthermore, the government's efforts to increase access to healthcare services across the country have led to an increase in the number of patients seeking treatment for these conditions.
Local special circumstances: Zambia's healthcare system is still in the process of being developed, and this has led to a number of challenges in the immunosuppressants market. For example, there is a shortage of healthcare professionals, particularly in rural areas, which can make it difficult for patients to access the care they need. Additionally, there are issues with drug availability and affordability, which can limit patients' options when it comes to treatment.
Underlying macroeconomic factors: Zambia's economy has been growing steadily in recent years, which has led to an increase in disposable income and a growing middle class. This has resulted in more people being able to afford healthcare services, including immunosuppressant therapy. Additionally, the country's population is growing, which is leading to an increase in the number of people who need healthcare services. Finally, the government has made healthcare a priority, which has led to increased investment in the sector and improved access to healthcare services for the population.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
